Effect of timing of pulmonary metastasis occurrence on the outcome of metastasectomy in osteosarcoma patients
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Jul 2018 · 1 min read
In brief
In brief
Retrospective study of 88 osteosarcoma patients who underwent pulmonary metastasectomy shows timing of metastasis significantly impacts survival. Patients with metastases appearing after chemotherapy completion had best outcomes (52% 5-year survival), while those developing metastases during treatment had poorest prognosis (8% 5-year survival).
Written by the GCMD Library team from the article.
Background
Complete metastasectomy is the best predictor of survival in patients with osteosarcoma pulmonary metastases. There has been some controversy in the literature regarding the prognostic significance of the timing of occurrence of lung metastasis.
Methods
We reviewed the clinical course of all osteosarcoma patients with pulmonary metastases treated by metastasectomy in our hospital from January 2008 through December 2016. Each patient who underwent metastasectomy was placed into one of three groups based on whether lung metastases were present at initial presentation (Group 1), developed during chemotherapy (Group 2), or appeared after completion of chemotherapy (Group 3). Data were obtained retrospectively and follow-up was obtained until the end of June 2017.
Results
We identified 170 patients with pulmonary nodules of whom 99 (58.2%) underwent at least one metastasectomy (149 thoracotomies). Eleven patients had benign pulmonary nodules and were excluded. The other 88 patients were classified as Group 1 (37), Group 2 (18) or Group 3 (33). The median follow-up was 35 months (range 8 to 99). Postmetastasis 5-year overall survival (OS) was 38.1 ± 6.4%; event-free survival (EFS) was 25 ± 5.3%. By group, postmetastasis 5-year OS and EFS were 34.3 ± 13% and 18 ± 9.3% in Group 1, 8 ± 6.5% and 6.5 ± 5% in Group 2, and 52 ± 11.4% and 25 ± 9% in Group 3 (P